NICE Endorses Sparsentan as a Viable Treatment for IgA Nephropathy in England
On May 23, 2025, CSL Vifor announced that the National Institute for Health and Care Excellence (NICE) in England has issued final draft guidance in favor of using FILSPARI® (sparsentan) as a treatment option for adult patients suffering from primary IgA nephropathy. This condition, characterized by the accumulation of IgA in the kidneys, can lead to significant kidney dysfunction and ultimately kidney failure. As one of the most common types of primary glomerular disease worldwide, it affects over 22,000 adults in England alone.
Sparsentan is particularly noteworthy as it represents the first non-immunosuppressive dual-action therapy recommended for patients with IgA nephropathy. Specifically, it’s suitable for adults exhibiting a urine protein excretion of 1.0 g/day or more or a urine protein-to-creatinine ratio of at least 0.75 g/g. NICE’s endorsement is primarily based on positive results from the phase-III PROTECT trial, which demonstrated statistically significant reductions in proteinuria among patients treated with sparsentan compared to those given irbesartan.
The clinical implications of NICE’s recommendation are substantial. It implies that sparsentan has been recognized not only for its clinical efficacy but also for its value in providing cost-effective treatment options for healthcare systems. Within 90 days of the guidance's final publication, the NHS must ensure that funding for this treatment is made available—a timeline that is projected for June 27, 2025.
Professor Jonathan Barratt, an expert in renal medicine at the University of Leicester, expressed his enthusiasm regarding the decision, calling it a major advancement for patients. He highlighted the critical need for effective treatments given that many patients diagnosed with IgA nephropathy might eventually face renal failure.
IgA nephropathy leads to damage in the kidney's glomeruli due to the accumulation of faulty IgA, resulting in conditions like hematuria (blood in urine) and proteinuria (excess protein in urine). With treatment, the goal is to manage proteinuria, which is a key risk factor in the disease's progression. Despite existing options, many patients still struggle to achieve adequate proteinuria reduction and face a grim prognostic outlook—approximately 30-40% of patients may progress to kidney failure within a decade of diagnosis.
CSL Vifor is enthusiastic about the prospects of making sparsentan available in the UK, anticipating a launch in the latter half of 2025, following the approval from the UK regulatory bodies. The company aims to work closely with the NHS to facilitate prompt access to this essential therapy, fulfilling a vital need in treating IgA nephropathy.
Notably, sparsentan acts as a dual antagonist of both the endothelin A receptor and the angiotensin II subtype 1 receptor—molecules integral to kidney function. This novel dual-action mechanism showcases the drug's potential in addressing kidney disorders more comprehensively compared to traditional treatments. The PROTECT trial, which served as a foundational study for NICE's endorsement, was a key multi-centred, double-blind investigation that evaluated sparsentan's safety and efficacy against irbesartan. Preliminary results indicated sparsentan significantly reduced proteinuria, suggesting a promising avenue for advanced chronic kidney disease patients.
IgA nephropathy often progresses silently, and the journey to diagnosis can be lengthy, usually beginning with early symptoms like persistent back pain or hypertension. However, with innovative treatments like sparsentan on the horizon, there is newfound hope that patients will have better therapeutic options to help manage their condition.
CSL Vifor’s push for sparsentan aligns with broader objectives to enhance kidney health globally. With significant resources dedicated to nephrology and chronic kidney disease advancements, the company reinforces its commitment to improving patient outcomes. As the situation unfolds, the emphasis will be on ensuring that those impacted by IgA nephropathy receive the prompt and effective care they deserve.
Sparsentan is particularly noteworthy as it represents the first non-immunosuppressive dual-action therapy recommended for patients with IgA nephropathy. Specifically, it’s suitable for adults exhibiting a urine protein excretion of 1.0 g/day or more or a urine protein-to-creatinine ratio of at least 0.75 g/g. NICE’s endorsement is primarily based on positive results from the phase-III PROTECT trial, which demonstrated statistically significant reductions in proteinuria among patients treated with sparsentan compared to those given irbesartan.
The clinical implications of NICE’s recommendation are substantial. It implies that sparsentan has been recognized not only for its clinical efficacy but also for its value in providing cost-effective treatment options for healthcare systems. Within 90 days of the guidance's final publication, the NHS must ensure that funding for this treatment is made available—a timeline that is projected for June 27, 2025.
Professor Jonathan Barratt, an expert in renal medicine at the University of Leicester, expressed his enthusiasm regarding the decision, calling it a major advancement for patients. He highlighted the critical need for effective treatments given that many patients diagnosed with IgA nephropathy might eventually face renal failure.
IgA nephropathy leads to damage in the kidney's glomeruli due to the accumulation of faulty IgA, resulting in conditions like hematuria (blood in urine) and proteinuria (excess protein in urine). With treatment, the goal is to manage proteinuria, which is a key risk factor in the disease's progression. Despite existing options, many patients still struggle to achieve adequate proteinuria reduction and face a grim prognostic outlook—approximately 30-40% of patients may progress to kidney failure within a decade of diagnosis.
CSL Vifor is enthusiastic about the prospects of making sparsentan available in the UK, anticipating a launch in the latter half of 2025, following the approval from the UK regulatory bodies. The company aims to work closely with the NHS to facilitate prompt access to this essential therapy, fulfilling a vital need in treating IgA nephropathy.
Notably, sparsentan acts as a dual antagonist of both the endothelin A receptor and the angiotensin II subtype 1 receptor—molecules integral to kidney function. This novel dual-action mechanism showcases the drug's potential in addressing kidney disorders more comprehensively compared to traditional treatments. The PROTECT trial, which served as a foundational study for NICE's endorsement, was a key multi-centred, double-blind investigation that evaluated sparsentan's safety and efficacy against irbesartan. Preliminary results indicated sparsentan significantly reduced proteinuria, suggesting a promising avenue for advanced chronic kidney disease patients.
IgA nephropathy often progresses silently, and the journey to diagnosis can be lengthy, usually beginning with early symptoms like persistent back pain or hypertension. However, with innovative treatments like sparsentan on the horizon, there is newfound hope that patients will have better therapeutic options to help manage their condition.
CSL Vifor’s push for sparsentan aligns with broader objectives to enhance kidney health globally. With significant resources dedicated to nephrology and chronic kidney disease advancements, the company reinforces its commitment to improving patient outcomes. As the situation unfolds, the emphasis will be on ensuring that those impacted by IgA nephropathy receive the prompt and effective care they deserve.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.